PriceTargets.com logo

Eloxx Pharmaceuticals - ELOX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/23/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ELOX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eloxx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELOX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELOX

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Eloxx Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ELOX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Eloxx Pharmaceuticals. This rating has held steady since March 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/11/2023OppenheimerBoost Target$50.00 ➝ $55.00
4/6/2023OppenheimerReiterated RatingOutperform$50.00
1/5/2023OppenheimerLower Target$120.00 ➝ $50.00
5/23/2022Piper SandlerLower TargetOverweight$4.00 ➝ $1.50
5/9/2022HC WainwrightLower Target$1.00
1/24/2022B. RileyLower Target$5.00 ➝ $3.00
12/16/2021OppenheimerInitiated CoverageOutperform$4.00
11/18/2021HC WainwrightLower TargetPositive ➝ Neutral$2.00 ➝ $1.00
11/11/2021HC WainwrightLower TargetNeutral$3.00 ➝ $2.00
7/7/2021MizuhoReiterated RatingBuy$3.10
6/29/2021MizuhoInitiated CoverageBuy$3.10
5/27/2021B. RileyInitiated CoverageBuy$5.00
5/19/2021Piper SandlerLower TargetOverweight$6.00 ➝ $4.00
11/9/2020HC WainwrightReiterated RatingNeutral
6/10/2020CitigroupDowngradeBuy ➝ Neutral$11.00 ➝ $4.00
5/8/2020Janney Montgomery ScottLower TargetBuy$13.00 ➝ $10.00
5/8/2020Piper SandlerLower TargetOverweight$10.00 ➝ $6.00
3/9/2020CitigroupLower TargetNeutral$31.00 ➝ $11.00
3/6/2020Janney Montgomery ScottLower TargetBuy$14.00 ➝ $13.00
3/6/2020Piper SandlerLower Target$14.00 ➝ $10.00
3/6/2020HC WainwrightReiterated RatingNeutral$10.00 ➝ $3.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Eloxx Pharmaceuticals logo
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.28
Low: $0.00
High: $0.70

52 Week Range

Now: N/A

Volume

N/A

Average Volume

7,939 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Eloxx Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Eloxx Pharmaceuticals in the last year:
View the latest analyst ratings for ELOX.

What is the current price target for Eloxx Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Eloxx Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Eloxx Pharmaceuticals in the next year.
View the latest price targets for ELOX.

What is the current consensus analyst rating for Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ELOX.

What other companies compete with Eloxx Pharmaceuticals?

Other companies that are similar to Eloxx Pharmaceuticals include Amgen, Gilead Sciences, argenx, BioNTech and Biogen. Learn More about companies similar to Eloxx Pharmaceuticals.

How do I contact Eloxx Pharmaceuticals' investor relations team?

Eloxx Pharmaceuticals' physical mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company's listed phone number is (781) 577-5300 and its investor relations email address is [email protected]. The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com. Learn More about contacing Eloxx Pharmaceuticals investor relations.